Biotech Values

[DewDiligence]

ABBV/ENTA—Were you surprised by the high GT3 SVR4 rates 96% (27/28), 96% (27/28), 97% (29/30) and 93% (27/29) in Arms D, E, F, and G?

I would have found these SVR4 numbers for ABT-493/ABT-530 in GT3 patients surprisingly strong if not for the tip-off from ABBV’s Morgan Stanley webcast in mid September (#msg-117120410).

Many investors assume NS5B nucleotides are the cornerstone of future pan-genotypic HCV regimens and Viekira will be obsolete in 2 years.

Those are two distinct points. V-Pak may be obsolete in two years if ABT-493/ABT-530 is non-inferior to V-Pak in GT1 efficacy; however, this doesn’t imply that future HCV regimens must include a nuke to be competitive. (ABT-493/ABT-530 does not contain a nuke.)